Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10289-10297

  Lei, Wang ^a,b   Devarajan, Eswaran ^a   Jin, He ^a   Reddy, Sekhar P ^c   Le Dai, Jia ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN D1; HISTONE DEACETYLASE; PROTEIN KINASE SYK; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER GROWTH; CANCER INHIBITION; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; ENZYME SUBUNIT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME PRECURSORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 28544449211     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2231     Document Type: Article

References (38)

1. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
2. Yuan YF, Mendez R, Sahin A, Dai JL. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res 2001;61:5558-61.
3. Coopman PJ, Do MTH, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000;406:742-7.
4. Toyama T, Iwase H, Yamashita H, et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett 2002;189:97-102.
5. Dejmek J, Leandersson K, Manjer J, et al. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 2005;11:520-8.
6. Wang L, Duke L, Zhang PS, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 2003;63:4724-30.
7. Moroni M, Soldatenkov V, Zhang L, et al. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004;64:7346-54.
8. Mahabeleshwar GH, Kundu GC. Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3-kinase activity in breast cancer cells. J Biol Chem 2003;278:6209-21.
9. Ruschel A, Ullrich A. Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells. Cell Signal 2004;16:1249-61.
10. 1-integrin signaling and inflammatory responses in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288: L497-507.
11. Wang L, Pan Y, Dai JL. Evidence of prooncogenic activity of MKK4 in breast and pancreatic tumors. Oncogene 2004;23:5978-85.
12. Hu L, Wang J, Baggerly K, et al. Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics 2002;3:16.
13. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz V. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000;21:148-54.
14. Woodside DG, Obergfell A, Leng L, et al. Activation of Syk protein tyrosine kinase through interaction with integrin β cytoplasmic domains. Curr Biol 2001;11:1799-804.
15. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002;12:142-8.
16. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
17. Adiseshaiah P, Papaiahgari SR, Vuong H, Kalvakolanu DV, Reddy SP. Multiple cis-elements mediate the transcriptional activation of human fra-1 by 12-O-tetradecanoylphorbol-13-acetate in bronchial epithelial cells. J Biol Chem 2003;278:47423-33.
18. Suske G. The Sp-family of transcription factors. Gene 1999;238:291-300.
19. Buckley M, Sweeney K, Hamilton J, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
20. Motokura T, Bloom T, Kim HG, et al. A novel cylin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5.
21. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto AJ. Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 1994;102:695-8.
22. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
23. 1/S phase transition by expression of cyclin D1 and E with an inducible system. Mol Cell Biol 1994;14:1669.
24. Ewen ME. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 1994;13:45.
25. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
26. Bergers G, Graninger P, Braselmann S, Wrighton C, Busslinger M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol Cell Biol 1995;15:3748-58.
27. Reichmann E, Schwarz H, Deiner EM, et al. Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. Cell 1992;71:1103-16.
28. Saez E, Rutberg SE, Mueller E, et al. c-fos is required for malignant progression of skin tumors. Cell 1995;82:721-32.
29. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
30. Roy D, Calaf G, Hei TK. Profiling of differentially expressed genes induced by high linear energy transfer radiation in breast epithelial cells. Mol Carcinog 2001;31:192-203.
31. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 2001;7:2213-21.
32. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulate proliferation and invasiveness of breast cancer cells. Oncogene 2005;24:1434-44.
33. Kustikova O, Kramerov D, Grigorian M, et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998;18:7095-105.
34. Harbour JW, Dean DC. Chromatin remodeling and Rb activity. Curr Opin Cell Biol 2000;12:685-9.
35. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci U S A 1998;95:10493-8.
36. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
37. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10:4109-17.
38. Kumar AP, Butler AP. Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 1999;137:159-65.